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Platelet-Derived Growth Factor (PDGF) is a dimeric protein which exists in 
PDGF-AA, PDGF-AB, and PDGF-BB isoforms. PDGF has been shown to play a 
major role in wound healing and the migration and the proliferation of 
vascular cells. The PDGF isoforms interact with a dimeric PDGF receptor, aa, 
ap, or pp, which exhibit isoform binding specificities. We identified the 
proliferative and migratory influences of the PDGF isoforms on bovine aortic 
endothelial cells (BAECs), rat epididymal fat pad capillary endothelial cells 
(RFCs), and bovine aortic smooth muscle cells (BASMCs). 
In cells grown on Type I collagen (2D culture), treatment of BAECs with 
the isoforms of PDGF did not affect migration or proliferation. Treatment of 
RFCs and BASMCs with PDGF-AB (10 ng/ml) resulted in 27% and 13% increases 
in proliferation (p=0.006, p=0.048). BASMCs given PDGF-AB (10 ng/ml) had an 
11% increase in migration (p=0.035). RFCs and BASMCs treated with PDGF-BB 
(10 ng/ml) had a 100% and 50% increases in proliferation (p<0.001, p=0.002). 
There was a 22% increase in migration of the BASMCs treated with PDGF-BB 
(p<0.001). 
In cells grown in a Type I collagen gel (3D culture), treatment of 
BAECs and RFCs with the PDGF isoforms did not result in a change in 
proliferation. Conversely, proliferation increased 13% in BASMCs given PDGF- 
AA, 23% in cells given PDGF-AB, and 42% in BASMCs treated with PDGF-BB. 
We conclude that the PDGF isoforms have similar effects in RFCs and 
BASMCs in 2D culture in that PDGF-AB and PDGF-BB are promoters of five day 
proliferation which may be regulated through the p subunit of PDGF receptors. 
Conversely, the PDGF isoforms do not affect the behavior of BAECs. In addition, 
RFCs grown in 3D culture do not respond to PDGF treatment while BASMCs do, 
suggesting that RFCs are a cell population capable of modulating their 





Platelet-Derived _ Growth Factor 
Platelet-Derived Growth Factor (PDGF) is a 30-34k mw heat stable, 
basic, dimeric protein whose two polypeptide chains are linked by disulfide 
bonds. The two chains, A chain and B chain (both 17k mw), are coded for 
by different genes located on chromosomes 7 and 22, respectively but share 
60% amino acid homology including eight cysteine residues (1-4). 
Waterfield, et al. and Doolittle, et al. have demonstrated that the B chain is 
the cellular proto-oncogene (c-sis) homologous to transforming simian 
sarcoma virus protein (\-sis) (5,6). The A and the B chains can associate in 
any dimeric combination giving rise to three possible PDGF isoforms: 
PDGF-AA, PDGF-AB, and PDGF-BB. 
Even before the identification of the individual isoforms it was 
found that PDGF is differentially secreted by a variety of cells including 
platelets, macrophages, vascular endothelial and smooth muscle cells, 
fibroblasts, and neoplastic cells including malignant gliomas, mammary 
carcinomas, colonic adenocarcinomas, adrenal carcinomas, non-small cell 
lung carcinomas, melanomas, fibrosarcomas, and osteosarcomas (7-16). 
PDGF is a potent mitogen for mesenchymal cells and has therefore been 
associated with many actions in different cell types including the ability to 
affect migration and proliferation of vascular cells, promote wound 
healing, induction of cytoskeletal changes, and the ability to affect the 
differentiation of progenitor cells along specific paths during normal 
development. 
Through some of the above mechanisms, PDGF has been linked 
extensively to atherogenesis and ischemia. Specifically, Bell and Madri 
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found that PDGF increases both the migration and proliferation of bovine 
aortic smooth muscle cells but PDGF inhibited both proliferation and 
migration in bovine aortic endothelial cells, suggesting a role for 
neointimal development by smooth muscle migration and subsequent 
atheroma formation which may also serve as a nidus of platelet 
aggregation (17). Furthermore, not only has PDGF been shown to be a 
mitogen for vascular smooth muscle cells in vitro (and therefore without 
the benefit of a non-thrombogenic surface) but Golden, et al. have 
demonstrated that vascular smooth muscle cells are capable of secreting 
PDGF even under an intact endothelium (18). Evidence for the cytoskeletal 
manifestations of PDGF treatment on migration comes from Mallestrom, et 
al. who have demonstrated membrane ruffling (also shown to be associated 
with actin reorganization) in human foreskin Fibroblasts. This was felt to 
be a reaction specific for PDGF in that it was reversible with anti-PDGF 
antibodies (19). In addition to PDGFs effect on migration and proliferation 
and their role in vascular pathology, PDGF has been shown to be a potent 
vasoconstrictor causing contraction when added to fresh isolates of rat 
aorta (PDGF is more potent than Angiotensin II in this model), thus adding 
the possibility of increased vascular tone and vasospasm to underlying 
atherosclerosis with their resulting contribution to ischemia (20). 
With regard to the beneficial effects of PDGF, Greenhalgh, et al. 
demonstrated that PDGF improved wound healing in diabetic mice who 
received large full-thickness skin wounds compared to those who received 
similar wounds but were not treated with PDGF. Wound healing was 
considered to be improved given that there was an increased number of 
fibroblasts and capillaries seen at 10 and 21 days after injury and improved 
wound closure see at 21 days (21). PDGF is also implicated in normal 
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developmental pathways. Noble, et al. and Richardson, et al. have 
elucidated the role that PDGF plays in differentiation of bipotential 
oligodentrocyte/type-2 astrocyte progenitor cells (22,23). In this system, 
type-1 astrocytes secrete growth factors (largely PDGF) which act on the 
bipotential progenitor cells causing them to differentiate into 
oligodendrocytes (which will myelinate neurons in the central nervous 
system) or into type-2 astrocytes (which are associated with nodes of 
Ranvier). In addition, it has been demonstrated that PDGF promoted 
progenitor cell motility and inhibits the premature differentiation of 
progenitor cells into oligodendrocytes. 
The identification of the PDGF isoforms has led to the finding that 
the secretion of individual isoforms is specific for a given cell type. For 
instance, 80% and 90% of mammary carcinoma cell lines tested by Peres, et 
al. produced both PDGF-A chain and PDGF-B chain respectively (11) but 
many other cells secrete only one type of chain. Vascular smooth muscle 
cells have been shown to secrete only PDGF-A chain whether the adjacent 
intima was intact or had been subjected to denudation injury (18,24). 
Fingerle, et al. showed an increased secretion of only the A chain after 
denudation. Some vascular endothelial cells, conversely, produce large 
amounts of B chain but very little A chain (25,26). Mendoza, et al. have 
demonstrated the increased production of PDGF-A chain mRNA (but not B 
chain mRNA) by smooth muscle cells in the gravid versus non-gravid 
uterus and have proposed that PDGF-A chain is intimately linked with 
uterine expansion during pregnancy (27). O'Donnell, et al. found that 
human embryonal cell carcinomas secrete PDGF-A chain (13). 
PDGF-B chain has been localized in macrophages during all stages 
of atherogenesis (8) and the homodimer of PDGF-B chain (PDGF-BB) 
■ I 
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improved healing of full thickness skin wounds in diabetic mice (21), 
Beckmann, et al. suggest that the PDGF-B chain has a greater ability to 
transform cells than PDGF-A chain which is consistent with the finding 
that the PDGF-B chain is homologous to the c-sis proto-oncogene (28). 
Some investigators have suggested that the actions of PDGF-BB and the PDGF 
heterodimer, PDGF-AB, are similar, differing only with respect to intensity 
of response, whereas the actions of PDGF-AA are often disparate from those 
of the PDGF isoforms which contain a B chain. Siegbahn, et al. 
demonstrated that PDGF-AB and PDGF-BB have chemotactic effects on 
monocytes and fibroblasts whereas PDGF-AA does not (29). Similarly, 
Hammacher, et al. have demonstrated that only PDGF-AB and PDGF-BB are 
capable of causing the membrane ruffling and actin reorganization seen 
in human foreskin fibroblasts (30). The PDGF receptor has been implicated 
in generating this vast number of actions that PDGF has on effector cells. 
Platelet-Derived Growth Factor Receptor 
The PDGF receptor is composed of a dimer of two 170-180 kDa 
transmembrane proteins in the split tyrosine kinase family which uses 
this activity as its intracellular signalling mechanism. The receptor is a 
dimer consisting of a or p subunits and associate as either homo- or 
heterodimers: act, ap, pp. The receptor subunits share 44% homology, both 
contain five immunoglobulin-like domains extracellularly, and both 
contain intracellular split tyrosine kinase domains (31,32). Because each 
receptor subunit possesses a specific PDGF chain preference, the receptor 
dimers differentially bind the PDGF isoforms (Figure 1). Specifically, the a 
receptor subunit will bind either PDGF-A chain or PDGF-B chain whereas 
the P receptor subunit will only bind the PDGF-B chain. Based on these 
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specificities, a (3(3 receptor will bind PDGF-BB with the greatest affinity, 
PDGF-AB to a slight degree, and PDGF-AA not at all. An aa PDGF receptor, 
conversely, will bind all three isoforms of PDGF (33,34). 
Once the PDGF molecule is bound to the receptor, there is 
internalization of the receptor-ligand complex resulting in a 
phosphorylation-mediated conformational change in the PDGF receptor 
(which only takes place in the presence of ATP) which induces the 
tyrosine kinase activity (35,36). Sorkin, et al. demonstrated that while the 
intrinsic tyrosine kinase enhances receptor-ligand internalization, it was 
not an essential for this action (35). Westermark, et al. found that tyrosine 
kinase activity was necessary for membrane ruffling, cytoskeletal 
reorganization, and migration. Porcine aortic endothelial cells transfected 
with tyrosine kinase negative P(3 receptors did not exhibit these actions 
while those with the wild-type PP receptor did (36). While the exact 
sequence of events remains elusive, it is generally held that ligand binding 
stimulates the breakdown of phosphotidyl inositol bisphosphate followed 
by the generation of inositol trisphosphate and diacylglycerol as second 
messengers. Inositol trisphosphate promotes the release of intracellular 
calcium stores while diacylglycerol leads to the activation of protein kinase 
C (37,38). Sachinidis, et al., found a detectable increase in diacylglycerol 
within 20 seconds after the addition of recombinant PDGF-AB or PDGF-BB to 
rat aortic smooth muscle cells. In these cells, PDGF-AA had a slower and 
highly variable ability to stimulate diacylglycerol production. This 
production peaked at one minute with a six-fold increase in diacylglycerol 
and a fall off to its stable and half-maximal concentration six minutes after 
stimulation. Reasonably low doses of PDGF-AB or PDGF-BB (1-30 ng/ml) 
caused a seven to twelve-fold increase in inositol trisphosphate production 
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in rat aortic smooth muscle cells while PDGF-AA had no effect on inositol 
trisphosphate production in these cells (39). 
Given that there are only three PDGF receptor configurations and a 
multitude of cell responses to PDGF, Gronwald, et al. have postulated that the 
multitudinous effects of PDGF are a reflection of differing absolute and 
relative numbers of receptor types expressed on cells (40). Lee, et al. have 
identified the a receptor subunit which possesses tyrosine kinase activity 
in the cDNA library of rat olfactory epithelium (41). Werner, et al. have 
evidence that both a and p receptor subunits exist on the surface of 
cultured Kaposi sarcoma cells (42). Hermansson, et al. have identified a but 
not P receptor subunits in human glioma cells, whereas Wang, et al. have 
identified functional PDGF receptors containing the p subunit in cultured 
human meningioma cells (9,43). Similarly, Heldin, et al. demonstrated p 
receptor subunits in an anaplastic thyroid carcinoma (10). Given that 
PDGF-AB and PDGF-BB were the only isoforms to cause membrane ruffling 
and actin reorganization, Hammacher, et al. deduced that PDGF interaction 
with the P receptor subunit was essential for this action (30). Recently, 
Yablonka-Reuveni, et al. demonstrated that mouse C-2 myoblasts (derived 
from adult skeletal muscle) express pp receptors. When stimulated with the 
different isoforms of PDGF, PDGF-BB causes a five-fold increase in cell 
proliferation with a decrease in differentiation (as measured by the 
amount of myosin in cells) compared to the cells treated with PDGF-AA and 
PDGF-AB (44). Expanding on Gronwald's idea that the actions of PDGF in 
different cell types are a reflection of the absolute and relative differences 
in receptor expression, the addition of independent regulation of A and B 
chains can explain the multitudinous effects of PDGF. 
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PDGF and PDGF Receptor Interaction 
Mercola, et al. illustrated that both the A and B chains of PDGF and 
the a and p receptor subunits are expressed differentially and may be 
under independent control (45). These investigators found that only PDGF- 
A chain was expressed in mouse embryonic and extraembryonic tissue at 
6.5 to 8.5 days and that while both a and p receptor subunits are expressed 
in the mouse embryo, the a subunit is expressed both earlier and to a 
greater degree than the P subunit. Several neoplastic cell lines have been 
shown to contain both PDGF receptors and the ability to secrete PDGF. 
Hermansson, et al. and Nister, et al. illustrated this point in malignant 
glioma cell lines suggesting the possibility of an autocrine loop as a 
mechanism for neoplastic growth (9,46). This interaction is not confined to 
embryogenesis and neoplasia, however. Majesky, et al. proposed a two 
phase process in arterial repair after balloon catheter denudation injury to 
rat carotid arteries (47). In the acute phase (first six hours) they observed 
a significant decrease in the amount of P subunit expressed on smooth 
muscle cells while seeing a 10-12-fold increase in the amount of PDGF-AA 
expressed and no change in either PDGF-B chain or a subunit expression. 
In the chronic phase of repair (two weeks after injury) the smooth muscle 
cells expressed a smaller amount of a subunit mRNA but an increased 
amount of p subunit mRNA expression. In addition there may be 
differential expression of PDGF receptor subunits and secretion of specific 
PDGF chains in the same cell type in this model. Specifically, the smooth 
muscle cells which were located on the luminal side, i.e., close to the site of 
the denudation injury, expressed a larger amount of PDGF-A chain and P 
receptor subunit than smooth muscle cells located farther away from the 
site of intimal damage. 
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Expression of PDGF receptor subunits may also be affected by other 
growth factors. Gronwald, et al. describe a phenomenon they term 
"transmodulation" in which Transforming Growth Factor-p (TGF-P) 
regulates the expression of PDGF receptor subunits (48). These 
investigators found that quiescent 3T3 cells which were treated with 24 
hours of TGF-P bound almost no PDGF-AA and PDGF-AB, but had only a 40% 
reduction in their ability to bind PDGF-BB compared to controls. As 
expected, these cells also expressed a diminished number of a receptor 
subunits while the number of P receptor subunits was increased. 
B&&fcai£fe_Ons-siims 
Investigators have identified the structure of PDGF and its function 
in many different cell types. Much of the work elucidating PDGF's 
function, however, was performed before the specific isoforms and the 
receptor binding specificities were recognized. In addition, while the 
mitogenic effect of PDGF on vascular smooth muscle cells is well 
characterized, the effect of PDGF on vascular endothelial cells is still under 
investigation. Bar, et al. found that PDGF did not affect ^H-thymidine 
incorporation (a measure of DNA synthesis and therefore an indirect 
measure of proliferation) in large vessel endothelial cells (bovine aorta 
and pulmonary artery), whereas there was increased ^H-thymidine in 
small vessel endothelial cells (bovine fat and mouse brain capillaries) (49). 
Conversely, Bell and Madri did identify an effect in large vessel endothelial 
cells. Specifically, these authors found that PDGF decreased the migration 
and proliferation of bovine aortic endothelial cells (17). Both of these 
studies, however, were performed before the isolation of the different PDGF 
isoforms and the advent of recombinant technology. In the present study, 
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I will use functional assays which measure migration and proliferation to 
determine whether the specific PDGF isoforms have differing actions on 
endothelial cells and vascular smooth muscle cells and whether different 
types of endothelial cells (namely small and large vessel endothelial cells) 
react differently to PDGF treatment. 
Secondly, Madri, et al. have demonstrated some cell populations can 
modulate their phenotype depending on the environment in which they 
are cultured. Environmental changes which have been shown to 
influence cell morphology include extracellular matrix components, 
soluble factors, and culturing cells in a three-dimensional collagen gel (50) 
(versus the traditional two-dimensional culture system). I seek to compare 
the phenotypic responses of endothelial and vascular smooth muscle cells 




Cells and Culture 
Microvascular endothelial cells were cultured by Ms. Adeline 
Tucker from the fat pad capillaries of rat epididymides (RFCs) as described 
by Madri and Williams (51). Briefly, the epididymal fat pad of 400 g 
Sprague-Dawley rats were removed from recently sacrificed animal and 
placed in sterile Williams HEPES buffer (NaCl 140mM, HEPES lOmM, KC1 
lOmM, CaCl2 O.lmM, MgCl2 0.2mM, NaHC03 11.9 g/1, glucose 5.0 g/1, pH 7.4). 
Pieces of fat which appeared to be free of large blood vessels were minced 
and placed in a solution of HEPES buffer and collagenase (Type II 250 mg/50 
ml HEPES buffer, Sigma). After incubation at 37° with agitation (for 
approximately one hour), the suspension was centrifuged at 200 g for 
seven minutes. The pellet was washed in HEPES buffer and 5% bovine 
serum albumin twice and then centrifuged at 200 g for five minutes. The 
pellet was then resuspended in 45% Percoll (Pharmacia Fine Chemicals) 
and recentrifuged at 15,000 g for 20 minutes resulting in identifiable 
capillary tufts in the tissue isolate. The tufts were then washed with HEPES- 
bovine serum albumin buffer and then plated on 60-mm Petri dishes 
previously coated with 12.5 mg/ml Type I and Type III collagen in medium 
(199 E, Gibco) with 20% fetal bovine serum, penicillin, streptomycin, and 
glutamine. To this medium was added an equal amount of 10% fetal bovine 
serum medium conditioned by confluent bovine aortic endothelial cells. 
This medium was used to maintain the RFC population (RFC medium). The 
cells were maintained in an incubator containing 5% CO2, 95% humidified 
atmostphere at 37°C. 

The cells were passaged to 1:3 split ratio when confluent 
(approximately every seven days) in 0.2% trypsin with EDTA. The 
endothelial cell origin of these cells was confirmed by the presence of 
angiotensin-converting enzyme activity and reactivity with anti-factor 
VIII (data not shown, see ref 51). Passages four through ten were used for 
experiments. 
The large vessel endothelial cells, i.e., vessels which contain both 
intima and media, used in the following experiments were bovine aortic 
endothelial cells (BAECs) and were isolated from calf aorta by Ms. Adeline 
Tucker (52). The vessel was obtained from a slaughterhouse and was 
washed in iced phosphate buffered saline (PBS) with penicillin, 
streptomycin, and fungisone added. The aortic adventitia was dissected 
from the vessel and both ends of the aorta were cannulated. The intima was 
washed with a PBS/penicillin/streptomycin solution and then with a 
solution of 20% 199E medium (Gibco) with penicillin and streptomycin 
added. The distal end of the aorta was then clamped and the lumen was 
filled 199E medium with collagenase 1 mg/ml (Worthington) and was 
incubated for 30 minutes. 
The media/collagenase solution was removed and the lumen was 
then washed with 20% heat-inactivated fetal bovine serum 199E medium 
containing glutamine, penicillin, and streptomycin. The aorta was then 
massaged and the contents of the lumen were plated on a 75 cc tissue 
culture flask and were incubated at 37°C with 5% CO2. 
The cells were fed 10% fetal bovine serum medium (DM, Gibco) 
supplemented with glutamine, penicillin, and streptomycin twice weekly. 
This medium containing 10% fetal bovine serum was used to maintain the 
BAEC and bovine aortic smooth muscle cell (BASMC) populations (10% FBS 
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medium). The cells were passaged at a 1:3 split ratio when confluent (about 
every seven days) in 0.2% trypsin with EDTA. The endothelial cell origin of 
these cells was confirmed by the presence of angiotensin-converting 
enzyme activity and reactivity with anti-factor VIII (data not shown, see 
ref 51). Passages four through ten were used for experiments. 
Bovine aortic smooth muscle cells (BASMCs) were isolated by Ms. 
Adeline Tucker from fresh calf aorta obtained from a slaughterhouse (52). 
Using sterile conditions, each aorta was cut lengthwise to expose the 
intima. The intimal surface was rubbed with sterile gauze to denude the 
endothelium. The most intimal layer of smooth muscle cells was teased 
away in strips from the remaining media using sterile forceps and was 
then placed in a Petri dish. These strips were then minced to a very fine 
consistency and were then covered with a small amount of 10% FBS medium 
so that the minced strips remain in contact with the Petri dish. After 
several days, the smooth muscle cells which were later used for culture 
migrated away from the minced strips. The cells were fed 10% fetal bovine 
serum medium (DM, Gibco) supplemented with glutamine, penicillin, and 
streptomycin twice weekly. The cells were passaged at a 1:3 split ratio 
when confluent (about every seven days) in 0.2% trypsin with EDTA. 
Passages two through five were used for experiments. 
Proliferation of Cells in Two-Dimensional Cultures 
Petri dishes were coated with Type I collagen (12.5 pl/ml dissolved 
in a sodium carbonate buffer at pH 9.3), stored overnight at 4°C, and washed 
three times with warm PBS and 2 ml of medium was placed in each dish. 
The cells, whether BAECs, RFCs, or BASMCs, were prepared by trypsinizing a 
75 mm tissue culture flask and resuspending the cells in medium. A 
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suspension of 1.4 x 104 cells in 1.5 ml medium was added to each of the 
dishes and the dishes were incubated for six hours at 4°C in a 5% CO2 
incubator. After six hours, the cells were treated with either RFC or 10% 
FBS medium (depending on which cell type was used) containing no PDGF 
(control group) or medium containing a specific PDGF isoform and were 
reincubated. The cells were fed medium containing their treatment at 
three days. After one, two, or five days the dishes were treated with 0.2% 
trypsin to lift the cells from the dish and the absolute number of cells/ml 
was determined using a Coulter Counter. 
2-H Thymidine Incorporation 
Quantitative ^H-thymidine uptake has been used as an indication of 
DNA synthesis and therefore as an indirect measure of cell proliferation. 
Approximately 12,000 BASMCs were plated onto a 24-well bacteriologic 
culture dish that had been coated with Type I collagen (12.5 pg/ml). The 
BASMCs were allowed to attach to the matrix for six hours and were then 
treated with 10% FBS medium containing a specific PDGF isoform (10 
ng/ml) or without any growth factor (control) and were incubated for 24 
or 48 hours at 37°C. In a radioactive hood, the cells were treated with a 1% 
solution of ^H-thymidine in 10% FBS medium and were incubated at 37°C for 
4 hours. The cells were washed with PBS and were treated with a 
methanol/acetic acid solution (3:1) for ten minutes. The cells were then 
treated with a chilled 20% trichloroacetic acid solution (in ddH20) and were 
then washed with PBS. The cells were left in a 0.2M NaOH solution at 37°C 
overnight. The cell/NaOH solution was added to 3.5 ml of Optifluor solution 
(Packard) and placed in a scintillation vial. The radioactivity was measured 
using a Bechman LS 300 scintillation counter. 
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Proliferation of Cells in Three Dirnensign$al_Q}lLLLrg^ 
Evaluation of cell proliferation in three dimensions was performed 
by suspending and culturing cells in a Type I collagen gel as described by 
Madri, et al. (53). To prepare the gel, lyophilized bovine calf dermis was 
suspended in sterile 10 mM acetic acid (5 mg/ml) and was stirred overnight 
at 4°C overnight. A known amount of the Type I collagen solution was 
placed in a cold, sterile 50 cc tube and ten percent of this volume of HESS 
was added. Approximately 50 pi of IN NaOH were added in 10 pi aliquots to 
the solution, vortexing after each addition, until the pH indicator changed 
from yellow to pink which indicated a pH of 7.0. BAECs, RFCs, or BASMCs 
were added to the Type I collagen suspension until a concentration of 106 
cells/ml was reached. 
The cells were added to millicells (0.5 ml/millicell) placed in a 24- 
well culture dish and were incubated at 37°C for several minutes until the 
gel solidified. RFC or 10% FBS medium (with or without PDGF) was added to 
the 24-well culture dish and the gel was incubated at 37°C. The cells were 
fed with media with or without PDGF the following day and on day three. 
After five days, the collagen gel was washed five times with PBS and 
were digested in 3 ml of a collagenase solution consisting of PBS, type II 
collagenase at 1 mg/ml (Sigma), CaCl2 ImM, and MgCl2 ImM. The gels were 
digested in this solution for approximately an hour in a 37°C shaking water 
bath. An equal volume of medium was added to the digested gel solution, 
and an aliquot of this new solution was used for counting the cells in either 




Cell migration was determined using a radial migration assay 
described by Pratt, et al. (54). Prior to the migration assay, 35 mm 
bacteriologic Petri dishes (Falcon) were coated with 2 ml of Type I collagen 
(12.5 pl/ml) dissolved in a sodium carbonate buffer at pH 9.3. The dishes 
were kept overnight at 4°C. The dishes were washed three times with warm 
sterile PBS and 2 ml of 10% FBS medium was added to each dish. 
Stainless steel fences (approximately 4 cm in diameter, 1 cm high, 
with a 1 cm hole cut in the center; see ref 52) were added to each of the 
Petri dishes and the media contained in the center well was removed. A 
BAEC or BASMC cell suspension which was made by trypsinizing a 75 mm 
tissue culture flask and resuspending the lifted cells in 10% FBS medium 
and 0.4 ml of this cell suspension was placed in the center well of each of 
the fences. The dishes were incubated in a 37°C, 5% CO2 incubator for six 
hours to allow attachment and confluence of the suspended cells. 
After six hours, the fences were removed thus releasing the cells 
from contact inhibition and allowing the cells to migrate radially. At the 
time the fences were removed, the cells were washed with PBS to remove 
any nonadherent cells and were then treated with the specific 
experimental treatment being investigated. In the case of cells treated 
with Platelet-Derived Growth Factor (PDGF), whether the given treatment 
was PDGF-AA, PDGF-AB, or PDGF-BB, 1.5 ml of medium containing 10 ng/ml 
PDGF was added to each dish. The cells treated with 10% FBS medium alone 
served as controls. New medium containing the same treatment was added 
to each dish after three days. 

After five days, the cells were fixed in 10% buffered formalin and 
stained with hematoxylin. The areas covered by the radially migrating 
cells were traced using MacMeasure (Yale Shareware). 
Data Analysis 
Data were analyzed using CLINFO, an NIH-sponsored statistical 
analysis program. Data were analyzed using Student's t-Test (unpaired, 2 
tailed). For comparisons of more than two conditions, the data were 
analyzed using Analysis of Variance with Newman-Keuls Multiple Range 
Test to test for significant differences between individual treatment 
groups. Data are expressed as mean +_ standard error and significance was 




Proliferation in Two Dimensional Cultures: Dosage in RFCs 
The dose response that each PDGF isoform had on proliferation was 
measured in RFCs, The effects were measured after five days based on cells 
grown on collagen Type I in 0.5% fetal bovine serum medium and the doses 
of each PDGF isoform used were 0.625 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5.0 
ng/ml, and 10.0 ng/ml (Figure 2). 
When the proliferation of RFCs was measured in cells receiving 
different doses of PDGF-AA, there was no significant change in 
proliferation compared to control treatment regardless of the dose of PDGF- 
AA used (Figure 2). Specifically, the change in proliferation ranged from a 
9% decrease in those cells treated with PDGF-AA at 0.625 ng/ml to a decrease 
in proliferation of 38% in those cells treated with PDGF-AA at 1.25 ng/ml. 
There was no increase in proliferation in any of the groups treated with 
PDGF-AA and all of the treatment groups were not significantly different 
from those cells treated with 10% fetal bovine serum alone. 
Some of the doses of PDGF-AB were associated with an increase in 
proliferation in RFCs as seen in Figure 2. Treatment with PDGF-AB at 0.625 
ng/ml resulted in a 6% increase in proliferation (p=NS) while cells treated 
with PDGF-AB at 1.25 showed a 24% increase in proliferation (p=NS). Cells 
treated with PDGF-AB at a dose of 2.5 ng/ml had a 33% increase in 
proliferation compared to control (p=0.010). Those RFCs treated with PDGF- 
AB at 5.0 ng/ml showed a 60% increase in proliferation compared to control 
(p=0.001 vs control, p<0.05 vs 0.625 ng/ml, 1.25 ng/ml, and 2.5 ng/ml). The 
RFCs treated with PDGF-AB at 10.0 ng/ml demonstrated a 63% increase in 
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proliferation compared to control cells (p=0.004, also p<0.05 vs 1.25 ng/ml, 
2,5 ng/ml, 5.0 ng/ml). 
RFCs treated with some doses of PDGF-BB also showed an increase in 
proliferation compared to cells treated with 0.5% fetal bovine serum 
medium alone at some doses (Figure 2). Cells treated with 0.625 ng/ml 
showed a 45% increase (p=NS) while RFCs treated with PDGF-BB at 1.25 
ng/ml had a 79% increase in proliferation (p=0.027). Cells treated with 
PDGF-BB at 2.5 ng/ml demonstrated a 118% increase in proliferation 
compared to control (p=0.Q01, p<0.05 compared to 0.625 ng/ml). The group 
treated with 5 ng/ml had a 163% increase in proliferation compared to the 
cells treated with medium alone (p<0.001, and p<0.05 compared to 0.625 
ng/ml and 1.25 ng/ml). Finally, the RFCs that were treated with PDGF-BB at 
a dose of 10.0 ng/ml had a 195% increase in proliferation compared to 
control (p=0.002, p<0.05 compared to 5 ng/ml, 2.5 ng/ml, and 1.25 ng/ml). 
Proliferation of Two Dimensional Cultures;_Dosage in BASMCs 
The dose response of the PDGF isoforms were examined by Dr. 
Martin Marx in BASMCs in 0% fetal bovine serum medium on Type I 
collagen (Figure 3). These cells were grown in two dimensions and 
absolute cell number was measured after five days. The doses of each 
isoform used were 1.25 ng/ml, 2.5 ng/ml, 5/0 ng/ml, 10.0 ng/ml, and 20.0 
ng/ml. 
As in RFCs, treatment with PDGF-AA was not associated with 
significant changes in proliferation of BASMCs regardless of the dose tested 
as seen in Figure 3. Specifically, the responses ranged from a 12% increase 
in proliferation compared to control with PDGF-AA at 1.25 ng/ml to a 6% 
decrease in proliferation with PDGF-AA at 20.0 ng/ml. 
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When BASMCs were treated with PDGF-AB, some of the doses tested 
were associated with significantly increased proliferation compared to 
cells treated with 0% fetal bovine serum medium alone (Figure 3). PDGF-AB 
at a dose of 1.25 ng/ml resulted in a 6% increase in proliferation (p=NS) 
while cells treated with with 2.5 ng/ml had a 32% increase in proliferation 
(p=0.016, p<0.05 vs 1.25 ng/ml). Those BASMCs treated with PDGF-AB 5.0 
ng/ml had a 43% increase in proliferation compared to the control group 
(p=0.007, p<0.05 vs 1.25 ng/ml). Treatment with PDGF-AB atlO.O ng/ml was 
associated with a 60%increase in cell number compared to control cells 
(p<0.001, p<0.05 compared tol.25 ng/ml and 2.5 ng/ml). This proliferation 
was somewhat diminished when PDGF-AB 20 ng/ml was the treatment, with 
the BASMCs having a 56% increased proliferation over the control cells 
(p-0.001, p<0.05 compared to 1.25 ng/ml and 2.5 ng/ml). 
As in the RFCs, BASMCs which were treated with increasing doses of 
PDGF-BB demonstrated increasing degree of proliferation compared to 
BASMCs treated with 0% fetal bovine serum medium alone as illustrated in 
Figure 3. Those BASMCs given PDGF-BB 1.25 ng/ml had a 1.3% decrease in 
proliferation compared to control (p=NS) while giving PDGF-BB 2.5 ng/ml 
to these cells was associated with a 12% increase in proliferation (p=NS). 
The BASMCs treated with PDGF-BB at 5.0 ng/ml proliferated 26% more than 
control cells (p=0.024), while cells which received PDGF-BB 10.0 ng/ml had 
a 56% increased proliferation (p=0.011, p<0.05 compared to 1.25 ng/ml, 2.5 
ng/ml, 5.0 ng/ml). Those BASMCs which received PDGF-BB 20.0 ng/ml had 
a 129% increased proliferation compared to control cells (p<0.001, p<0.05 
compared to 1.25 ng/ml, 2.5 ng/ml, 5.0 ng/ml, 10.0 ng/ml). 
Based on the above data in both RFCs and BASMCs, the dosage used to 
compare the differing effects of the PDGF isoforms was 10.0 ng/ml in that 
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this dose fell well above the dose needed to generate increased proliferation 
in both RFCs and BASMCs for both PDGF-AB and PDGF-BB. 
Proliferation of Cells in Two Dimens.i.ona.l-£ulture&:_Five Day Data (IQ 
ng/m!) 
The treatment of BAECs with PDGF-AA, -AB, and -BB at 10 ng/ml did 
not significantly affect five day cell proliferation in two dimensional 
cultures (13%, 9%, and 23% increase compared to control, respectively; 
Figure 4). 
When RFCs grown in two dimensional cultures were treated with 
the PDGF isoforms at 10 ng/ml, each isoform had a different effect on cell 
proliferation after Five days (Figure 5). When treated with PDGF-AA, the 
RFCs had only a 6% increase in proliferation compared to controls (those 
treated with RFC medium with no added PDGF, p=NS), while those RFCs that 
were treated with PDGF-AB had a 27% increase in proliferation (p=0.006, 
p<0.05 compared to PDGF-AA group). When RFCs were treated with PDGF-BB, 
there was 100% increase in proliferation compared to controls (p<0.001, 
p<0,05 compared to PDGF-AA, and PDGF-AB groups). 
When BASMCs grown in two dimensional culture were treated with 
10 ng/ml PDGF isoforms in 10% FBS medium, those cells treated with PDGF- 
AA showed a 1% decrease in proliferation compared to controls after five 
days (p=NS; Figure 6). The BASMCs treated with PDGF-AB showed a 13% 
increase in proliferation (p=0.048), and those cells treated with PDGF-BB 
showed a 50% increase in proliferation compared to control cells (p=0.002, 
p<0.05 compared to PDGF-AA, PDGF-AB). 
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Early Proliferation of BASMCs in Two Dimensional Culture;_Cdi„Nmb-£I 
In order to determine whether the PDGF isoforms exhibit their 
actions at different points in time, the 24 and 48 hour proliferation was 
measured by counting the number of BASMCs grown in two dimensional 
culture (Figure 7). 
After 24 hours, those BASMCs treated with PDGF-AA (10 ng/ml) 
showed a 14% increase in cell number (p=NS). Those cells given PDGF-AB 
had a 24% increase in cell number (p=0.012), and those BASMCs treated with 
PDGF-BB demonstrated a 54% increase in cell number (p=0.0Q7). 
After 48 hours, the BASMCs treatment with PDGF-AA was associated 
with a 29% increase in cell number (p=0.003), while treatment with PDGF- 
AB resulted in a 15% increase in the number of cells (p=0.028). Treatment 
of BASMCs with PDGF-BB was associated with a 65% increase in cell number 
at this point in time (p<0.001). 
Early Proliferation of BASMCs in Two Dimensional Culture: 2-H-Thymidine 
Incorporation 
DNA synthesis in BASMCs grown in two dimensional cultures 
measured by ^H-thymidine incorporation has traditionally been used as an 
indirect measure of cell proliferation. In the present study, the - 
thymidine incorporation after PDGF treatment was compared to changes in 
proliferation as measured by cell counts (Figure 8). 
After 24 hour treatment with specific PDGF isoforms (10 ng/ml in 
10% FBS medium), those BASMCs treated with PDGF-AA expressed a 28% 
increase in scintillation counts compared to control (p=0.004) (Figure 7). 
Those cells treated with PDGF-AB showed a 19% increase (p=0.014), and 
those cells treated with PDGF-BB had a 4% decrease in scintillation counts 
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(p=NS). After treatment for 48 hours, the BASMCs which received PDGF-AA 
showed a 91% increase in radioactivity (pcO.OOl) (Figure 8), while those 
treated with PDGF-AB had a 31% increase (p=0.023). Those BASMCs 
receiving PDGF-BB for 48 hours had a 53% increase in radioactivity 
compared to control (p=0.001). 
Proliferation of Cells in.Three Dimensional Cultures 
When the five day proliferative effects of PDGF-AA, -AB, and -BB (10 
ng/ml) were measured in BAECs grown in a Type I collagen gel, there was 
no significant difference between the treated cells and the control cells 
(5% increase, 4% decrease, and 6% increase, respectively) (Figure 9). 
Similarly, Dr. Martin Marx found that the proliferation of RFCs grown in 
three dimensional culture and treated with PDGF-AA, -AB, -BB (10 ng/ml) 
did not differ significantly from control (1%, 6%, and 7% decrease 
respectively) (Figure 10). 
When the effects of the different PDGF isoforms were measured in 
BASMCs, there was a strong trend toward significance which could not be 
analyzed statistically because of small sample sizes (Figure 11). 
Specifically, those BASMCs treated with PDGF-AA (10 ng/ml) had a 13% 
increase in cell number after four days, while those which were treated 
with PDGF-AB had a 23% increase in cell number. Those BASMCs which 
received PDGF-BB demonstrated a 42% increase in cell number. 
Migration 
PDGF did not affect the degree of radial migration in BAECs grown 
on Type I collagen (Figure 12). Specifically, treatment with PDGF-AA, -AB, 
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and -BB (10 ng/ml) had a 0.3%, 1%, and 2.8% increase in migration, 
respectively. These differences were not statistically significant. 
BASMCs grown in 10% FBS medium had different reactions to 
treatment with the different isoforms of PDGF (Figure 13). The BASMCs that 
were treated with PDGF-A A at 10 ng/ml demonstrated a 1% increase in 
migration compared to those cells grown in 10% FBS medium alone (p=NS). 
The cells treated with PDGF-AB showed an 11% increase in migration 
compared to control (p=0.035 , p<0.05 compared to PDGF-AA), and those 
BASMCs treated with PDGF-BB had a 22% increase in migration compared to 
control (p<0.001, p<0.05 compared to PDGF-AA, and PDGF-AB). 
Previous experiements have demonstrated that RFCs will not 




The Effect of PDGF Isoforms 
Platelet-derived Growth Factor (PDGF) is a ubiquitous dimeric 
protein whose actions play a major role in normal development, neoplasia 
and both vascular injury and repair. In an attempt to further clarify the 
interaction between PDGF and vascular cells, large and small vessel 
endothelial cells and vascular smooth muscle cells were treated with the 
three isoforms of PDGF and proliferation and migration of these cells were 
measured. Previous work by Bell and Madri in bovine aortic smooth muscle 
cells (BASMCs) and bovine aortic endothelial cells (BAECs) treated with 
Mitomycin C illustrated that these two processes are independent (17). 
After five days of treatment with PDGF, a consistent relationship 
emerged with respect to the two dimensional proliferative and migratory 
responses of rat epididymal fat pad capillary endothelial cells (RFCs) and 
BASMCs to the specific isoforms of PDGF. Namely, when proliferation (i.e., 
absolute number of cells) was measured in RFCs and BASMCs treated with 
the different isoforms of PDGF grown in two dimensions, PDGF-AA did not 
induce a significant change compared to control cells. PDGF-AB was 
associated with a significant increase in proliferation in RFCs and BASMCs 
while the cells treated with PDGF-BB demonstrated a significant increase 
over control or cells treated with PDGF-AB. The same relationship held true 
for the radial migration of BASMCs. Specifically, the migration of those 
cells treated with PDGF-AA did not differ from control while those given 
PDGF-AB or PDGF-BB did. In addition, the cells treated with PDGF-BB 
migrated significantly more than those cells given PDGF-AB. 
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The relationship identified between the three isoforms of PDGF and 
increasing proliferation and migration is consistent with that identified by 
other investigations. The doses of PDGF used in these studies, however, 
varied somewhat. In general, the PDGF doses examined in the present study 
are within the range examined in other investigations. Siegbahn, et al. 
found that PDGF-AB and PDGF-BB were chemotactic for both monocytes and 
fibroblasts, but that PDGF-AA had no such effect (29). Sachinidis, et al. 
found that treatment with recombinant PDGF-AB and PDGF-BB (at doses 
between 3 and 10 ng/ml) was associated with increased ^H-thymidine 
incorporation, inositol trisphosphate release, increased intracellullar 
calcium, and diacylglycerol production in rat aortic smooth muscle cells 
(39). In a second study examining the effects of PDGF isoforms on rat aortic 
smooth muscle cells, Sachinidis, et al. found that PDGF-AB and PDGF-BB 
were also associated with an increase in intracellular pH, activation of the 
Na+/H+ exchanger, production of thromboxane A2, and caused contraction 
of smooth muscle cells (55). Westermark, et al. found that both membrane 
ruffling and actin reorganization took place in the presence of PDGF-AB or 
PDGF-BB (at 10 ng/ml to 100 ng/ml) and not in cells treated with PDGF-AA 
(56). These results are consistent with those found by Hammacher, et al. in 
which human foreskin fibroblasts treated with PDGF-AB and PDGF-BB 
demonstrated actin reorganization while those treated with PDGF-AA did 
not (30). Based on the relationship between specific chains of PDGF and its 
receptor subunit binding specificity (Figure 1), it is reasonable to presume 
that the proliferative response observed at five days in the present study is 
mediated by the interaction of PDGF-AB and PDGF-BB with the p receptor 
subunit. These isoforms will both bind to receptors containing a p subunit 
(PDGF-AB can bind to act or an aP receptors and PDGF-BB can bind to aa, ap, 
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or (3p receptors). Given that PDGF-AA is the only isoform which cannot 
bind to a receptor containing a P subunit and is the only isoform which did 
not elicit a migratory or proliferative response after five days, it is 
reasonable to infer that the p subunit of the PDGF receptor is intimately 
involved in these two actions. This conclusion, however, appears to be 
valid only when considering proliferation or possibly migration after 
several days. 
Two studies have identified a proliferative effect of PDGF-AA. 
Interestingly, this association was identified after a time interval 
substantially shorter than the initial experiments in this study, namely 
after 16 to 24 hours, by investigators using 3H-thymidine incorporation as 
their means of assessing proliferation. Sachinidis, et al. found that there 
was a variable degree of DNA synthesis in rat vascular smooth muscle cells 
after 20 hours of PDGF-AA exposure but this required doses in excess of 10 
ng/ml (52). Majak, et al. found that recombinant PDGF-AA used at a greater 
dose (50 ng/ml) was associated with significant 3H-thymidine uptake in rat 
aortic smooth muscle cells (57). In that study, incorporation was measured 
at 16 hours for sparsely grown cells and after 24 hours for confluent cells. 
Two of the experiments in the present investigation which demonstrated a 
proliferative response to PDGF-AA did so when 3H-thymidine incorporation 
was measured in BASMCs after 24 and 48 hours of PDGF-AA exposure (this 
response was generated at 10 ng/ml in contrast to the studies cited). 
Specifically, PDGF-AA generated a highly significant increase in DNA 
synthesis at 24 hours, while PDGF-AB treatment was associated with a more 
modest, but significant, increase. Given the receptor subunit binding 
specificities, it is likely that the early increase in 3H-thymidine 
incorporation in the BASMCs treated with PDGF-AA (which can bind only to 
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a a receptors) and PDGF-AB (which can bind to a a or a P receptors) 
represents interaction of the isoform with receptors containing an a 
subunit. After 48 hours of treatment with the PDGF isoforms, however, the 
BASMCs treated with each isoform had a significant increase in 
thymidine incorporation compared to control, with PDGF-BB showing the 
greatest increase in incorporation over the second 24 hour period. 
The observation that all of the isoforms of PDGF are associated with 
increased ^H-thymidine incorporation raises several interesting issues. 
First, several investigations cited used ^H-thymidine incorporation as an 
indirect measure of cell proliferation (50,57). While it is true that DNA 
synthesis (as measured by ^H-thymidine incorporation) is necessary for 
cell proliferation, an increase in ^H-thymidine uptake may not be an 
adequate surrogate for cell number as a measure of proliferation. Using 
cell number as the gold standard for cell proliferation in BASMCs 24 and 48 
hours after treatment with PDGF reflects essentially the same relationship 
between the isoforms identified in the five day proliferation experiments. 
These findings warrant further investigation with regard to the time 
course of proliferation after PDGF treatment. The observation that PDGF- 
AA treatment results in a dramatic increase in ^H-thymidine incorporation 
while only inducing a modest increase in cell number, while the opposite is 
true of PDGF-BB suggests that the a and P PDGF receptor subunits may be 
linked to different intracellular actions. Dr. Martin Marx has demonstrated 
that treatment of RFCs with PDGF results in phosphorylation of the 
membrane associated proto-oncogene c-src within 10 minutes regardless 
of which isoform is used (data not shown) (58). Phosphorylation of c-src 
has been associated with cytoskeletal reorganization in epithelial cells and 
decreased intercellular molecular transport (56,60). Bell, et al. have 
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recently demonstrated that BAECs transfected to overexpress c-src have an 
increased migratory rate compared to sham-transfected BAECs (61). After 
the phosphorylation of c-src, however, the specific intracellular events 
triggered by interaction of PDGF with the a and P subunit remain elusive. 
While some investigations have suggested that the actions which PDGF has 
on different cell types is a reflection of absolute and relative differences in 
PDGF receptor expression (45,47), the observations generated by Dr. Marx 
and Bell, et al. illustrate what may be one of many intracellular steps 
needed to generate the behavioral differences seen as a result of treatment 
with the PDGF isoforms. 
The Effect of PDGF on_Speeific Vascular Cell Types 
This study sought to illustrate some of the differences between large 
and small vessel endothelial cells by virtue of the way in which they react 
to treatment with PDGF. Specifically, treating microvascular capillary 
endothelial cells, RFCs in this case, with PDGF elicited different responses 
than treating large vessel endothelial cells, e.g., BAECs, with PDGF. 
The differential effects that PDGF has on the two dimensional 
proliferation of BAECs and RFCs illustrates that, while both are endothelial 
cell cultures, these cells represent very different populations. Specifically, 
RFCs treated with PDGF isoforms demonstrated increased proliferation 
while BAECs did not. This observation that capillary and arteriolar 
endothelial cells respond differently to PDGF is consistent with the findings 
of Bar, et al. (49). In their study, bovine fat and mouse brain capillary 
endothelial cells treated with PDGF showed increased ^H-thymidine 
incorporation, a-amino isobutyric acid and 2-deoxyglucose uptake, while 
these events did not occur in bovine aortic and pulmonary artery 
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endothelial cells. In addition, 125I-PDGF bound to the microvascular 
endothelial cells but not the large vessel endothelial cells. Conversely, Bell 
and Madri found that PDGF inhibited both proliferation and migration of 
bovine aortic endothelial cells (17). Both of these studies, however, were 
conducted before the isolation of the individual PDGF isoforms and before 
recombinant forms of the isoforms were generated. Given the disparity 
between the observation found in investigations using "PDGF" (before the 
isolation of specific isoforms), with isoforms which were isolated, and now 
with recombinant PDGF isoforms, it is likely that the early PDGF 
preparations were contaminated with other growth factors. Despite their 
earlier Findings, Bell and Madri now think that the inhibition of migration 
and proliferation of BAECs they noted may have reflected contamination of 
the early PDGF preparations with TGF-0 (62). While several studies have 
evaluated the effects of nonrecombinant PDGF on endothelial cells and the 
effects of recombinant PDGF on vascular smooth muscle cells, it appears 
that this is the first investigation which compares the effects of the 
recombinant PDGF isoforms in large and small vessel endothelial cells. 
Interestingly, when BASMCs were treated with the PDGF isoforms, 
these cells behaved similarly to the RFCs cultured in two dimensions. 
Specifically, treatment with PDGF-BB and, to a lesser degree, PDGF-AB were 
associated with increased five day proliferation in both of these cell types. 
These isoforms did not affect proliferation in BAECs. Further evidence 
illustrating the similarities between these two populations comes from a 
western blot performed by Ms. Adeline Tucker (Figure 14) (63). This blot 
demonstrates that RFCs and BASMCs grown on Type I collagen (i.e., in two 
dimensions) express PDGF (3 receptor subunits whereas BAECs cultured in 
the same manner did not. While this finding does not preclude the 
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possibility of aa receptor expression on BAECs, antibodies to the a receptor 
subunit were not commercially available at the time the blot was done. 
However the lack of functional effects of PDGF in these cells make it 
unlikely that these cells express any PDGF receptors. The observation that 
RFCs cultured in two dimensions on Type I collagen are phenotypically 
similar to BASMCs and differ from large vessel endothelial cells is not a new 
one. In 1989, Kocher and Madri found that microvascular endothelial cells 
(RFCs) grown on specific extracellular matrix components including Type I 
collagen expressed a phenotype with features common to both endothelial 
cells and smooth muscle cells (64). Specifically, RFCs grown in two 
dimensions stained positively for the expression of Factor VIII and 
angiotensin-converting enzyme (both markers for endothelial cell 
differentiation and seen in BAECs) and also expressed a-smooth muscle- 
specific actin, a marker for smooth muscle differentiation. The list of 
phenotypic similarities between BASMCs and RFCs now includes the 
increase in proliferation associated with PDGF treatment and the common 
expression of PDGF p receptor receptor subunits in cells cultured in two 
dimensions. These findings support the hypothesis put forth by Kocher 
and Madri that RFCs and BASMCs may be closely related and may even be 
the descendents of a common progenitor cell (64). 
This hypothesis that BASMCs and RFCs have a common ancestor 
could be further strengthened with the tools available currently by 
examining a-smooth muscle-specific actin expression after stimulation 
with the different isoforms of PDGF. Several investigators have found that 
smooth muscle cells which are actively proliferating do not express a- 
smooth muscle-specific actin the way quiescent smooth muscle cells do. 
Studies by Bjorkerud, and Blank and Owens found that smooth muscle cells 
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treated with PDGF had an increase in DNA synthesis (i.e., they were actively 
proliferating) and a concomitant decrease in a-smooth muscle-specific 
actin (65,66). Both of these studies support the Finding that PDGF promotes 
smooth muscle cells to enter the cell cycle while decreasing expression of 
a-smooth muscle-specific actin. No study, however, has yet addressed the 
idea that the different PDGF isoforms may result in differential effects on 
a-smooth muscle-specific actin expression. Given the findings of the 
present study, it would be expected that all the isoforms would induce these 
changes, though at different points in time. In addition, if the same 
relationship between the PDGF isoforms and a-smooth muscle-specific actin 
held true in RFCs, it would strengthen the contention that BASMCs and RFCs 
are closely related. 
Modulation of Cell Phenotype in Two and Three Dimensional Cultures 
The similarities between RFCs and BASMCs, however, only hold true 
in two dimensional cultures. There was no increase in proliferation found 
when the effect of the PDGF isoforms on RFCs grown in three dimensional 
Type I collagen gels was measured. Conversely, BASMCs grown in three 
dimensions and treated with PDGF continued to demonstrate the same 
relationship between the isoforms identified in cells grown in two 
dimensions. Finally, BAECs grown in three dimensional culture failed to 
respond to PDGF treatment, consistent with the findings generated in two 
dimensions. This disparity in RFC proliferation in two and three 
dimensions is paralleled by the findings of Ms. Adeline Tucker who did not 
identify PDGF (3 receptor subunits on RFCs grown in three dimensions while 
present when RFCs were grown in two dimensions (Figure 14) (63). 
Further evidence of the phenotypic differences generated by culturing 
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RFCs in two and three dimensions comes from Kocher and Madri (64). 
These investigators found that RFCs cultured in a three dimensional Type I 
collagen gel did not express a-smooth muscle-specific actin as they had 
when cultured in two dimensions nor did they identify a-smooth muscle- 
specific actin in RFCs grown in vivo. This disparity between RFC 
morphology in two and three dimensional cultures was further described 
by Madri, et al. who reported that RFCs in three dimensions formed 
multicellular capillary-like tubes with lumina, form tight junctions, and 
develop distinct cell polarity (51). In contrast, RFCs cultured in two 
dimensions fail to form tubes, tight junctions, or specialized of regions of 
the cell membrane. These findings raise the question whether assessing 
RFC behavior based on two dimensional cultures is appropriate. Despite 
this, the finding that RFCs are cells capable of modulating their phenotype 
based on culture conditions while other types of endothelial cells (e.g., 
BAECs) cannot is not diminished and raises questions concerning the 
ancestry of RFCs as well as the pericyte. 
This ontologic question is pertinent when discussing the origin of 
the pericyte, the cell responsible for providing vascular tone to capillaries 
in the same fashion that smooth muscle cells provide tone for larger 
vessels. Because the pericyte expresses a-smooth muscle-specific actin, 
some contend that these cells are the descendants of smooth muscle cells 
which have migrated into capillary walls and redifferentiated to their 
pericytic morphology. The evidence generated by Madri and coworkers 
(50,54,64) and supported by the findings of the present investigation raise 
the possibility that capillary endothelial cells may be the progenitor of 
pericytes. Given that RFCs are plastic cells in that they behave like smooth 
muscle cells (including expressing markers of smooth muscle 
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differentiation) when cultured in two dimensions and like endothelial cells 
when cultured in three dimensions, this cell population seems a likely 
candidate as the progenitor of the pericyte. 
Conclusion 
The present study has demonstrated that the isoforms of PDGF have 
differing effects on selected vascular cells. Specifically, PDGF-AA is 
associated with increased DNA synthesis in BASMCs (an indirect 
measurement of cell proliferation) within the first 24 to 48 hours after 
stimulation and is diminished thereafter. This effect is probably mediated 
through the a receptor subunit of the PDGF receptor. Treatment with PDGF- 
AB and PDGF-BB was associated with an increase in cell proliferation and 
migration after several days. This effect is likely regulated through the p 
subunit of the PDGF receptor. 
This investigation also presented data which supported the 
argument that RFCs are a plastic cell population, capable of modulating its 
morphology based on external conditions. Specifically, it was demonstrated 
that RFCs, when cultured in two dimensions, expressed PDGF p receptor 
subunits and exhibited two dimensional proliferation which is similar to 
BASMCs. Conversely, when cultured in a three dimensional Type I collagen 
gel, RFCs lost their BASMC-like phenotype and behaved in a fashion similar 
to BAECs, large vessel endothelial cells. 
These findings point to several roles PDGF may play in clinical 
circumstances, including having a beneficial impact on wound healing. 
Greenhalgh, et al., in their study of skin wounds in diabetic mice found a 
dramatic increase in both the rate in strength of wounds treated with PDGF 
(21). In the first human trial of PDGF, Robson, et al. sprayed recombinant 
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PDGF-BB (100 pg/rnl) on chronic non-healing pressure sores (up to 165 
months old) for one month and found 96% decrease pressure sore volume 
compared to pretreatment (67). Histological examination of these wounds 
revealed an increased number of fibroblasts and endothelial cells in the 
healing wounds and there was no long-term evidence of hypertrophic 
scarring or keloid formation. Clinical settings such as this in which PDGF- 
generated increases in the cell migration and proliferation of the cells 
involved in wound healing is beneficial represent one possible use for 
exogenous forms of this growth factor. 
Settings in which migration and proliferation of these cells is 
detrimental represent another venue in PDGF research. To some degree, 
migration and proliferation of smooth muscle cells at the site of vascular 
injury is maladaptive in that it leads to neointima formation and 
perpetuates the cycle of vascular injury. Circumventing this process is 
considered to be one of the main challenges facing cardiovascular 
medicine especially with regard to the use of percutaneous transluminal 
coronary angioplasty. In this setting, endothelial denudation and 
exposure of the basement membrane to circulating platelets initiates the 
cascade which leads to stimualtion of smooth muscle cell proliferation, 
migration, and neointima formation by factors such as PDGF. Given this 
chain of events, it is understandable why restenosis after angioplasty 
remains a major problem in the long term success of this procedure. 
Recent investigations have turned toward the possible regulation of 
growth factor-induced smooth muscle cell migration and proliferation. 
Naftilan, et al. have identified a dramatic up-regulation of PDGF-A chain 
mRNA expressed in quiescent rat aortic smooth muscle cells when treated 
with Angiotensin II (68). Araki, et al. demonstrated that Angiotensin II 
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did not induce a mitogenic response in rabbit vascular smooth muscle 
cells, but that the combination of Angiotensin II and PDGF was associated 
with DNA synthesis to almost twice the degree induced by PDGF alone 
(69). Recent findings from Bell and Madri demonstrated both the 
Angiotensin Converting Enzyme Inhibitor, Lisinopril, and the 
Angiotensin II antagonist, Saralasin, were associated with 41% increase 
in bovine aortic endothelial cell migration (70). Conversely, the 
treatment of bovine aortic smooth muscle cells with these factors did not 
significantly affect migration. Treatment of the smooth muscle cells 
with Angiotensin II resulted in a highly significant increase in 
migration while the treatment of the endothelial cells with this factor 
had no effect. These observations have led to the belief that the PDGF 
and Angiotensin systems are intimately linked and it seems likely that 
the ability to regulate PDGF effects may come through manipulation of 
the Angiotensin system. It is clear that this line of research will have 




Figure 1. Platelet-Derived Growth Factor Binding Specificity. 

37 




Figure 2. Effects of the PDGF Isoforms at Differing Doses on the 
Five Day Proliferation of RFCs Cultured in Two Dimensions. 
*=Dose at which PDGF-BB differed from Control (1.25 ng/ml; 
p-0.027). **=Dose at which PDGF-AB differed from Control (2.5 































Figure 3. Effects of the PDGF Isoforms at Differing Doses on the 
Five Day Proliferation of BASMCs Cultured in Two Dimensions. 
*=Dose at which PDGF-BB differed from Control (5.0 ng/ml; 
p=0.024). **=Dose at which PDGF-AB differed from Control (2.5 





























Figure 4. Effects of the PDGF Isoforms at 10 ng/ml on the Five Day 





























Figure 5. Effects of the PDGF Isoforms at 10 ng/ml on the Five Day 



























Figure 6. Effects of the PDGF Isoforms at 10 ng/ml on the Five Day 






Figure 7. Effects of the PDGF Isoforms at 10 ng/ml on the 24 and 
48 Hour Proliferation of BASMCs Cultured in Two Dimensions as 





Figure 8. Effects of the PDGF Isoforms at 10 ng/ml on the 24 and 48 
Hour ^H-Thymidine Incorporation of BASMCs Cultured in Two 




Figure 9. Effects of the PDGF Isoforms at 10 ng/ml on Five Day 




























Figure 10. Effects of the PDGF Isoforms at 10 ng/ml on Five 
Day Proliferation of RFCs in Three Dimensional Culture. 
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Figure 11. Effects of the PDGF Isoforms at 10 ng/ml on Five Day 
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Figure 12. Effects of the PDGF Isoforms at 10 ng/ml on Five Day 


























Figure 13. Effects of the PDGF Isoforms at 10 ng/ml on Five Day 












Figure 14. Western Blot Illustrating PDGF Receptor Expression in BAECs (in 
two dimensions: 170kDa band absent), RFCs (in two dimensions: approx. 
170kDa bands present), RFCs (in three dimensions: 170kDa band absent), and 
BASMCs (in two dimensions: approx. 170kDa bands present). Blot courtesy of 
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